公开(公告)号：US09809573B2

公开(公告)日：2017-11-07

申请号：US15033770

申请日：2014-11-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Ling Chen ,  Gene M. Dubowchik ,  Swanee E. Jacutin-Porte ,  Prasanna Sivaprakasam ,  John E. Macor

IPC: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07D513/04 ,  C07D213/81 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D401/12 ,  C07D213/81 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07D513/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20150232480A1

公开(公告)日：2015-08-20

申请号：US14619213

申请日：2015-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Kevin Peese ,  Zhongyu Wang ,  John F. Kadow ,  Prasanna Sivaprakasam ,  B. Narasimhulu Naidu

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07D471/04

Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Abstract translation: 本公开一般涉及式I化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。 本公开提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。

公开(公告)号：US11053258B2

公开(公告)日：2021-07-06

申请号：US16463603

申请日：2017-11-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Prasanna Sivaprakasam ,  Gene M. Dubowchik ,  John E. Macor

IPC: C07D498/18 ,  C07D471/22 ,  C07D498/22 ,  A61P25/28 ,  A61P25/16 ,  A61P25/14

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

公开(公告)号：US10913741B2

公开(公告)日：2021-02-09

申请号：US17003385

申请日：2020-08-26

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Liqi He ,  Sanjeev Gangwar ,  Yam B. Poudel ,  Prasanna Sivaprakasam

IPC: A61K31/52 ,  A61K31/522 ,  C07D473/18 ,  C07D473/04 ,  A61P37/04 ,  A61K47/68

Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R1, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US20200291028A1

公开(公告)日：2020-09-17

申请号：US16890765

申请日：2020-06-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yam B. Poudel ,  Sanjeev Gangwar ,  Prasanna Sivaprakasam ,  Shoshana L. Posy

IPC: C07D473/18 ,  A61P37/04

Abstract: Compounds having a structure according to formula (I) where R1, R2, and R3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US10711003B2

公开(公告)日：2020-07-14

申请号：US16659735

申请日：2019-10-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Liqi He ,  Sanjeev Gangwar ,  Shoshana L. Posy ,  Yam B. Poudel ,  Prasanna Sivaprakasam

IPC: A61K31/52 ,  C07D473/18 ,  A61P37/04 ,  A61K47/60 ,  A61K47/68

Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US20200039986A1

公开(公告)日：2020-02-06

申请号：US16529457

申请日：2019-08-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yam B. POUDEL ,  Sanjeev Gangwar ,  Liqi He ,  Prasanna Sivaprakasam

IPC: C07D487/04 ,  A61K39/395 ,  A61K31/519 ,  A61K47/60

Abstract: Compounds according to formula II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

公开(公告)号：US10472361B2

公开(公告)日：2019-11-12

申请号：US16103210

申请日：2018-08-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yam B. Poudel ,  Sanjeev Gangwar ,  Prasanna Sivaprakasam ,  Shoshana L. Posy

IPC: C07D473/18 ,  A61P37/04

Abstract: Compounds having a structure according to formula (I) where R1, R2, and R3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.

公开(公告)号：US20190315714A1

公开(公告)日：2019-10-17

申请号：US16463467

申请日：2017-11-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Richard A. Hartz ,  Vijay T. Ahuja ,  Guanglin Luo ,  Ling Chen ,  Prasanna Sivaprakasam ,  Gene M. Dubowchik ,  Swannee E. Jacutin-Porte ,  John E. Macor

IPC: C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D417/14 ,  A61P25/28

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

公开(公告)号：US09718804B2

公开(公告)日：2017-08-01

申请号：US15033813

申请日：2014-11-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Ling Chen ,  Gene M. Dubowchik ,  Swanee E. Jacutin-Porte ,  Vivekananda M. Vrudhula ,  Senliang Pan ,  Prasanna Sivaprakasam ,  John E. Macor

IPC: C07D213/02 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D471/04

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.